MAY 28, 2014 6:00 AM PDT

The new role for HPV DNA testing: cobas HPV Test as a first-line cervical cancer screen

Speaker
  • Scientific Affairs Manager, Medical and Scientific Affairs, Roche Diagnostics
    Biography
      Dr. Julia Engstrom-Melnyk is a Scientific Affairs Manager within Medical and Scientific Affairs for Roche Diagnostics Corporation, supporting two geographic territories and serving as the scientific and clinical HPV subject matter expert for the U.S.  In these roles, she has collaborated with both North American and global colleagues on several high-profile projects and studies and has served as an invited speaker at both domestic and international conferences. Dr. Engstrom-Melnyk received her Ph.D. in Molecular Biology and Genetics from the University of Delaware, discovering and developing gene therapy approaches to treat genetically-inherited disorders.  As a Postdoctoral Fellow at Harvard Medical School/Beth Israel Deaconess Medical Center, her research explored signaling pathways following DNA damage and the biological processes of DNA repair.Dr. Julia Engstrom-Melnyk is a Scientific Affairs Manager within Medical and Scientific Affairs for Roche Diagnostics Corporation, supporting two geographic territories and serving as the scientific and clinical HPV subject matter expert for the U.S. In these roles, she has collaborated with both North American and global colleagues on several high-profile projects and studies and has served as an invited speaker at both domestic and international conferences. Dr. Engstrom-Melnyk received her Ph.D. in Molecular Biology and Genetics from the University of Delaware, discovering and developing gene therapy approaches to treat genetically-inherited disorders. As a Postdoctoral Fellow at Harvard Medical School/Beth Israel Deaconess Medical Center, her research explored signaling pathways following DNA damage and the biological processes of DNA repair.

    Abstract

    For the last 60 years the primary method of preventing cervical cancer in both the U.S. and Europe has been cervical cytology -- if it is negative, women are rescreen in three years and if positive, are referred to follow-up examinations. Although this strategy has led to a tremendous reduction in the incidence of cervical cancer, some significant limitations exist. Cytology has low sensitivity for cervical cancer pre-cursors, has low reproducibility, and does not adequately assess long-term risk. HPV testing added to cytology as a co-test for women 30 years and older increases the sensitivity of cytology and addresses many of its limitation, but also significantly contributes to the complexity of management. Additionally, it does not address the women 25-29 who are still screened with cytology alone. In ATHENA, 28% of all CIN3+ lesions detected were in women 25-29 -- more high-grade disease was found in these 6,647 women than in the 22,006 women 40 years and older. Further, cytology-based screening, the only other option for women 25-29, was negative in more than 57% of these cases, suggesting that current screening with cytology is inadequate in identifying underlying CIN3+ lesions in this age group. This is highly relevant when assessing data from the National Cancer Institute's SEER Tumor Registry, which shows a sharp rise in the incidence of invasive cervical cancer between the ages of 25 and 34 years. Since the goal of cervical cancer screening is to prevent cervical cancer from developing, it important to identify high-grade cervical cancer precursors in women 25-29 years, so that the precursors can be treated prior to this up rise in cervical cancer incidence and cervical cancer may be prevented. As a solution, HPV DNA testing can be used as a first-line primary screen in women 25 and older to not only enhance screening sensitivity but also reduce the complexity of a co-test.


    Show Resources
    You May Also Like
    MAY 11, 2021 10:00 AM PDT
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    C.E. CREDITS
    MAY 11, 2021 10:00 AM PDT
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    Date: May 11, 2021 Time: 10:00zm PDT Your samples are some of the most valuable assets in the laboratory. After spending countless hours on extraction and preparation, your conclusions could...
    NOV 16, 2020 8:00 AM PST
    C.E. CREDITS
    NOV 16, 2020 8:00 AM PST
    Date: November 16, 2020 Time: 8:00am (PST), 11:00am (EST) CRISPR screening has become the prime discovery tool in modern biomedical research and drug discovery. At the same time, most screen...
    JUN 09, 2021 7:00 AM PDT
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    C.E. CREDITS
    JUN 09, 2021 7:00 AM PDT
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    Date: June 9, 2021 Time: 09 June 2021, 7am PDT, 10am EDT, 4pm CEST cells with dramatic implications on the validity of past cell culture related research. The fact that at least 509 cell lin...
    NOV 18, 2020 8:00 AM PST
    C.E. CREDITS
    NOV 18, 2020 8:00 AM PST
    DATE: November 18, 2020 TIME: 08:00am PDT We develop and implement technologies to solve some of the major bottlenecks in biomedical research. In particular, we establish new imaging approac...
    OCT 29, 2020 6:00 AM PDT
    C.E. CREDITS
    OCT 29, 2020 6:00 AM PDT
    Date: October 29, 2020 Time: 6:00am (PDT), 9:00am (EDT), Chronic inflammation can occur as a result of a combination of genetic predispositions and environmental factors. Epigenetic modifica...
    APR 01, 2021 8:00 AM PDT
    C.E. CREDITS
    APR 01, 2021 8:00 AM PDT
    Date: April 01, 2021 Time: 8:00am (PST), 11:00am (EST) Generating therapeutic antibodies is far more challenging than obtaining antibodies that merely recognize their targets. Engineering po...
    MAY 28, 2014 6:00 AM PDT

    The new role for HPV DNA testing: cobas HPV Test as a first-line cervical cancer screen


    Specialty

    Behavior Sciences

    Clinical Medicine

    Cancer

    Medicine

    Health

    Disease

    Veterinary Sciences

    Therapy

    Behavior

    Geography

    North America100%

    Registration Source

    Website Visitors100%

    Job Title

    Facility/Department Manager100%

    Organization

    Clinical Laboratory50%

    Animal Hospital50%


    Show Resources
    Loading Comments...
    Show Resources
    Attendees
    • See more